Sign up
Log in
MARKET
AMGN
AMGN
Amgen Inc
NASDAQ
334.33
+0.03
+0.01%
Opening 15:39 07/26 EDT
OPEN
334.56
PREV CLOSE
334.30
HIGH
338.83
LOW
333.33
VOLUME
852.71K
TURNOVER
0
52 WEEK HIGH
346.85
52 WEEK LOW
221.30
MARKET CAP
179.34B
P/E (TTM)
47.77
1D
5D
1M
3M
1Y
5Y
1D
Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Amgen Inc. (NASDAQ:AMGN) has US$64.0b in debt. The company's balance sheet is a good indicator of its ability to pay off debt. Amgen's debt levels are higher than the company's free cash flow. Its interest cover ratio of 2.2 times is a sign of high leverage. But Amgen saw its EBIT drop 27% over the last 12 months. The balance sheet isn't the only thing to consider when looking at Amgen.
Simply Wall St · 10h ago
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
NASDAQ · 11h ago
Aristotle Global Equity Q2 2024 Commentary
Seeking Alpha · 12h ago
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
NASDAQ · 1d ago
Viking sends Lilly, Novo lower as obesity drug enters late-stage program
Seeking Alpha · 1d ago
HRTS: Generating Alpha In Obesity Treatment
Tema Obesity & Cardiometabolic ETF (HRTS) is a new actively managed fund focusing on the obesity treatment market. The fund includes a mix of cash flow-positive companies, high-growth companies, and start-ups with promising technology. Consensus price targets for the current portfolio point to 37% upside potential.
Seeking Alpha · 1d ago
QQQ ETF Update, 7/25/2024
TipRanks · 1d ago
What Lies in Store for Healthcare ETFs in Q2 Earnings?
NASDAQ · 2d ago
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.